tissue microarray chips (ZHUOLI IMAGING TECHNOLOGY CO LTD)
90
Structured Review
ZHUOLI IMAGING TECHNOLOGY CO LTD
tissue microarray chips
Tissue Microarray Chips, supplied by ZHUOLI IMAGING TECHNOLOGY CO LTD, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray+tissue+chips/tissue+microarray/pm39595554-86-1-12
Average 90 stars, based on 1 article reviews
Tissue Microarray Chips, supplied by ZHUOLI IMAGING TECHNOLOGY CO LTD, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray+tissue+chips/tissue+microarray/pm39595554-86-1-12
Average 90 stars, based on 1 article reviews
tissue microarray chips - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Microarray:Article Title: MicroRNA-6084 orchestrates angiogenesis and liver metastasis in colorectal cancer via extracellular vesicles. Article Snippet: .. 665 666 Article Title: Hypoxia-induced circPLOD2a/b promotes the aggressiveness of glioblastoma by suppressing XIRP1 through binding to HuR Article Snippet: .. A Article Title: Integration of histopathological images and immunological analysis to predict M2 macrophage infiltration and prognosis in patients with serous ovarian cancer Article Snippet: .. In addition, we used an Article Title: Hypoxia-induced circPLOD2a/b promotes the aggressiveness of glioblastoma by suppressing XIRP1 through binding to HuR. Article Snippet: .. A Article Title: USP41 plays carcinogenic roles in human cutaneous melanoma through PI3K/Akt signaling pathway. Article Snippet: strong invasiveness, many patients experience tumor metastasis during the treatment process, which makes treatment difficult [4, 5].. Although emerging therapeutic approaches, such as targeted therapy, i.e. BRAF and MEK inhibitors, and immunotherapy, i.e. PD-1/PD-L1 monoclonal antibodies, have been increasingly used to treat metastatic melanoma, there are still many limitations, such as tumor resistance, low mutation rate of common targeted genes in some patients, and the treatment of advanced melanoma is still very difficult [6].. Therefore, it is particularly important to further study the pathogenesis of melanoma and explore new therapeutic targets. Article Title: Inhibition of Sox4 Increases the Sensitivity of Drug-resistant Melanoma Cells to Cisplatin through the P38 Signaling Pathway. Article Snippet: Background: SRY-Box Transcription Factor 4 (Sox4) has been found to be overexpressed in a number of malignancies and is linked to medication resistance.. The underlying mechanism of Sox4 in cisplatin-resistant melanomas, however, remains unknown.. Methods: Immunohistochemistry (IHC) was used to examine the expression of Sox4 in melanoma, pigmented nevi, and normal skin tissue. Biomarker Discovery:Article Title: CD38 contributes to tumor progression and tumor microenvironment reshaping in epithelial ovarian cancer Article Snippet: .. Expressing:Article Title: CD38 contributes to tumor progression and tumor microenvironment reshaping in epithelial ovarian cancer Article Snippet: .. Article Title: USP41 plays carcinogenic roles in human cutaneous melanoma through PI3K/Akt signaling pathway. Article Snippet: strong invasiveness, many patients experience tumor metastasis during the treatment process, which makes treatment difficult [4, 5].. Although emerging therapeutic approaches, such as targeted therapy, i.e. BRAF and MEK inhibitors, and immunotherapy, i.e. PD-1/PD-L1 monoclonal antibodies, have been increasingly used to treat metastatic melanoma, there are still many limitations, such as tumor resistance, low mutation rate of common targeted genes in some patients, and the treatment of advanced melanoma is still very difficult [6].. Therefore, it is particularly important to further study the pathogenesis of melanoma and explore new therapeutic targets. other:Article Title: Development and validation of a prognostic model for predicting survival and immunotherapy benefits in melanoma based on metabolism-relevant genes. Article Snippet: Written informed consent was obtained from all patients for the acquisition of tissue material, the Ethics Committee of |